HAEMATO AG: HAEMATO AG: The Supervisory Board and the Executive Board have agreed that Mr Uwe Zimdars will leave the Executive Board of HAEMATO AG on June 30, 2020.
June 25, 2020 at 12:35 pm EDT
Share
DGAP-Ad-hoc: HAEMATO AG / Key word(s): Personnel
HAEMATO AG: HAEMATO AG: The Supervisory Board and the Executive Board have agreed that Mr Uwe Zimdars will leave the Executive Board of HAEMATO AG on June 30, 2020.
25-Jun-2020 / 18:31 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Mr Zimdars is currently Executive Board Member of HAEMATO AG and Supervisory Board Member of M1 Kliniken AG. Due to the takeover of shares in HAEMATO AG by M1 Kliniken AG as of July 1, 2020, it is not possible to excercise both functions in parallel.
Mr Zimdars chose the function of Supervisory Board Member at M1 Kliniken AG in order to be able to support both companies in the future.
The Supervisory Board of HAEMATO AG would like to thank Mr Zimdars for his successful engagement and the good cooperation.
About HAEMATO:
HAEMATO AG, founded in 1993, is a pharmaceutical company focusing on the growing markets of high-priced specialty pharmaceuticals in the indication areas of oncology and HIV as well as other chronic diseases.
HAEMATO AG is listed in the Basic Board (Open Market) of the Frankfurt Stock Exchange. Key figures on the HAEMATO AG share:
Subscribed capital: EUR 22,867,154
Listed class of shares: bearer ordinary shares
ISIN: DE000619070
WKN: 619070
Stock exchange code: HAE
25-Jun-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Haemato AG, previously Windsor AG, is a Germany-based pharmaceutical company. The Company trades and patent-free and patent-protected medicines and generic drugs with focus on oncology, human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS), neurology, rheumatology, urology, cardiovascular diseases and other chronic diseases. The Company's main markets are Europe, North America and Japan. It also imports medicines from within the European Economic Area in form of parallel imports and re-imports. The Company's subsidiaries are Haemato Pharm GmbH, Heamato Med GmbH, Castell Pharma BV, Sanate GmbH and Heamato Asia Co Ltd. Customers can order medicine through phone, fax and e-mail, among others.